Detalhe da pesquisa
1.
Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis.
Haemophilia
; 29(4): 1087-1094, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37347645
2.
Incidence and risk factors for surgical site infection after open reduction and internal fixation of intra-articular fractures of distal femur: A multicentre study.
Int Wound J
; 16(2): 473-478, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30588735
3.
No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study.
Mult Scler
; 23(13): 1736-1747, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28080250
4.
Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.
BMC Neurol
; 17(1): 29, 2017 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28183276
5.
In vivo maintenance of human regulatory T cells during CD25 blockade.
J Immunol
; 194(1): 84-92, 2015 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25416807
6.
Relationship between sustained disability progression and functional system scores in relapsing-remitting multiple sclerosis: analysis of placebo data from four randomized clinical trials.
Neuroepidemiology
; 44(1): 16-23, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25634764
7.
Predictors of long-term outcome in multiple sclerosis patients treated with interferon ß.
Ann Neurol
; 73(1): 95-103, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23378325
8.
Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
BMC Neurol
; 14: 240, 2014 Dec 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-25551571
9.
Does strategic coupling of TNCs affect their exit from host regions: Empirical analysis of the exit of Taiwanese enterprises from mainland China.
PLoS One
; 19(5): e0304254, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38787816
10.
Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor VIII Replacement in Severe Hemophilia A.
Adv Ther
; 41(6): 2267-2281, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38616241
11.
Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapies.
Eur Neurol
; 70(1-2): 35-41, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23689307
12.
Interaction and mediation effects of economic growth and innovation performance on carbon emissions: Insights from 282 Chinese cities.
Sci Total Environ
; 831: 154910, 2022 Jul 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35364175
13.
Evaluating Impact of Pulse Pressure on Indexes of Myocardial Work by Speckle-Tracking Echocardiography in Normotensive, Prehypertensive and Newly Diagnosed Hypertensive Patients.
Int J Gen Med
; 15: 1933-1943, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35228817
14.
Can collaborative innovation constrain ecological footprint? Empirical evidence from Guangdong-Hong Kong-Macao Greater Bay Area, China.
Environ Sci Pollut Res Int
; 29(36): 54476-54491, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35304715
15.
The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study.
BMC Neurol
; 11: 144, 2011 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-22074056
16.
VO2max as an exercise tolerance endpoint in people with cystic fibrosis: Lessons from a lumacaftor/ivacaftor trial.
J Cyst Fibros
; 20(3): 499-505, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33358691
17.
Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events.
J Cyst Fibros
; 20(2): 228-233, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32586736
18.
Peginterferon beta-1a reduces the evolution of MRI lesions to black holes in patients with RRMS: a post hoc analysis from the ADVANCE study.
J Neurol
; 264(8): 1728-1734, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28685353
19.
Measuring the impact of multiple sclerosis: Enhancing the measurement performance of the Multiple Sclerosis Impact Scale (MSIS-29) using Rasch Measurement Theory (RMT).
Mult Scler J Exp Transl Clin
; 3(3): 2055217317725917, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29104758
20.
Peginterferon beta-1a reduces disability worsening in relapsing-remitting multiple sclerosis: 2-year results from ADVANCE.
Ther Adv Neurol Disord
; 10(1): 41-50, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28450894